We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The labeling for Novartis’ kidney transplant drug Myfortic now carries a black box warning indicating that use of the drug during pregnancy is associated with increased risk of pregnancy loss and congenital malformations.